These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Petkau J; White R Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643 [No Abstract] [Full Text] [Related]
3. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172 [TBL] [Abstract][Full Text] [Related]
4. Subcutaneous recombinant interferon-beta-1a (Rebif): a review of its use in relapsing-remitting multiple sclerosis. Murdoch D; Lyseng-Williamson KA Drugs; 2005; 65(9):1295-312. PubMed ID: 15916455 [TBL] [Abstract][Full Text] [Related]
5. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology; 1999 Sep; 53(4):679-86. PubMed ID: 10489026 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Sandberg-Wollheim M; Hommes OR; Hughes RA; Paty DW; Abdul-Ahad AK Mult Scler; 1995; 1 Suppl 1():S48-50. PubMed ID: 9345399 [TBL] [Abstract][Full Text] [Related]
8. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Fernández O; Antiquëdad A; Arbizu T; Capdevíla A; de Castro P; Correa de Sa JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X Mult Scler; 1995; 1 Suppl 1():S67-9. PubMed ID: 9345404 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Minagara A; Murray TJ; Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940 [TBL] [Abstract][Full Text] [Related]
10. Spotlight on subcutaneous recombinant interferon-beta-1a (Rebif) in relapsing-remitting multiple sclerosis. Murdoch D; Lyseng-Williamson KA BioDrugs; 2005; 19(5):323-5. PubMed ID: 16207073 [TBL] [Abstract][Full Text] [Related]
11. Interferon beta treatment in relapsing-remitting multiple sclerosis. A review. Grigoriadis N Clin Neurol Neurosurg; 2002 Jul; 104(3):251-8. PubMed ID: 12127664 [No Abstract] [Full Text] [Related]
12. Treatment of multiple sclerosis with interferon beta-1 b. Abdul-Ahad A; Shah S; Galazka A Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626 [No Abstract] [Full Text] [Related]
13. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA; Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of magnetic resonance imaging sensitivity in patients with relapsing remitting multiple sclerosis: baseline versus Betaseron treatment trials. Frank JA; Bash C; Stone L; Petrella J; Maloni H; McFarland H Acad Radiol; 1996 Aug; 3 Suppl 2():S173-5. PubMed ID: 8796554 [No Abstract] [Full Text] [Related]
15. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M; Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242 [TBL] [Abstract][Full Text] [Related]
16. The treatment of multiple sclerosis: current and future. Polman CH; Hartung HP Curr Opin Neurol; 1995 Jun; 8(3):200-9. PubMed ID: 7551119 [TBL] [Abstract][Full Text] [Related]
17. Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response. Goodin DS Drugs; 2001; 61(12):1693-703. PubMed ID: 11693459 [TBL] [Abstract][Full Text] [Related]
18. What is new in the treatment of multiple sclerosis? Weinstock-Guttman B; Jacobs LD Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827 [TBL] [Abstract][Full Text] [Related]
19. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis. Chofflon M; Ben-Amor AF Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662 [No Abstract] [Full Text] [Related]
20. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]